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Background 
Antipsychotic use for behavioural and psychological symptoms of dementia (BPSD) is 
controversial.  Guidelines advise to reduce antipsychotics given the adverse effects and 
limited efficacy, to limit dose and treatment duration as well as to undertake discontinuation.  
Methods 
A pilot study with 40 hospitalised geriatric cognitively impaired patients, in which the effects 
of abrupt antipsychotic discontinuation were investigated, using neuropsychiatric inventory 
(NPI) scores before and one month after discontinuation.  Withdrawal symptoms were 
monitored three times a day with a checklist during five consecutive days.  
Results 
Participants (n=40) had a mean age of 84 years (range 67-95) and were in 53% male.  The 
total mean baseline NPI score was 21 (SD 12) with predominantly behavioural rather than 
psychological disturbances.  After abrupt discontinuation, mild withdrawal symptoms were 
observed in 72% of the patients, with frequencies of symptoms peaking on day 2 (53%) and 
day 3 (48%).  After one month, 31 patients (85%) were still off antipsychotics and improved 
on the majority of NPI domains, with a total mean NPI score decreasing from 18 (SD 13) to 
12  (SD 8, p=0.003).  In the relapse group, there was no deterioration associated with the 
abrupt discontinuation and subsequent resumption of therapy with a total mean NPI score 
decreasing from 31 (SD 12) at baseline to 27 (SD 8) at one month follow-up (p=0.345).  
Conclusion 
Abrupt antipsychotic discontinuation appears to be feasible.  Systematically performed 
discontinuation efforts in clinical practice are needed to differentiate between patients where 
antipsychotics have no added value and patients where the benefits outweigh the risks.   
 
 
 
 
 
 
 
 
Introduction 
The appropriateness of antipsychotic therapy for behavioural and psychological symptoms of 
dementia (BPSD) in older persons has been debated extensively and is a controversial topic.  
In fact, BPSD will affect about 50-80% of people with dementia, in varying degrees during 
their course of illness
1
.  Evidence suggests modest, limited efficacy for some specific 
symptoms within the BPSD spectrum
2
, but the potential of benefit is overshadowed by 
potential harm.  In the UK Banerjee
3
 (2009) concluded that there is minimal evidence for 
improvement in global behavioural disturbance by using antipsychotics (effect size 0.1-0.2), 
but a significant increase of absolute mortality risk.  Kleijer et al.
4
 (2009) reported that only 
18% of patients with dementia starting with antipsychotics improved on their behaviour, 
while 49% deteriorated.  Stroke, falls and consecutive fractures, cognitive decline as well as 
deep vein thrombosis
3,5
 have been reported as adverse effects of antipsychotics in older 
persons, and even in short-term trials
6
.  While trials had a time span of less than 12 weeks, 
antipsychotics are far more longer used in clinical practice
7
.  Therefore, serious concerns with 
regard to the long-term effects exist.  For all these reasons, guidelines
8,9
 advise to minimise 
antipsychotic use in older persons with dementia; to initiate antipsychotics only in severe 
distress after a risk-benefit analysis, and to limit treatment duration with attempts of 
discontinuation.  Few studies investigated antipsychotic discontinuation 
10-15
   and often with 
methodological limitations.  Moreover, the studies have not explored the possibility of 
discontinuation in a hospital setting, and the immediate effects of abrupt cessation with 
attention to withdrawal phenomena.  Mostly, they have focused on nursing home residents 
with  Alzheimer’s dementia; including only participants with mild symptoms; assessing 
different outcome measures on different times; including limited antipsychotic classes or not 
differentiating between antipsychotic or benzodiazepine withdrawal; and mostly 
implementing gradual discontinuation by tapering the dose. 
Our pilot study was an observational uncontrolled cohort study aiming to explore the 
feasibility of abrupt antipsychotic discontinuation in hospitalised, cognitively impaired 
geriatric patients, and the effects with regard to withdrawal phenomena, re-occurrence of 
neuropsychiatric symptoms, and relapse to antipsychotics over time. 
 
 
Methods 
 
Institutions and patients 
We conducted an observational study with hospitalised geriatric patients in a convenience 
sample of hospitals.  The feasibility of abrupt antipsychotic discontinuation was explored in 
long-term users, who should be considered for discontinuation in accordance with best care 
practice.  Patients were found eligible for study participation if:  
 they had a confirmed clinical diagnosis of dementia or cognitive impairment assessed 
by the Mini Mental State Examination (MMSE ≤ 25); 
 they used antipsychotics explicitly for behavioural and psychological symptoms; 
 the antipsychotic use was initiated before hospitalisation (at home or in the nursing 
home) or (in case of a long length of hospital stay) antipsychotics were used for at 
least one month during hospitalisation; and treating physician and researchers agreed 
on behavioural stability of the patient. 
For patients on high dose antipsychotics, an old age psychiatrist was consulted regarding the 
risk of severe withdrawal symptoms associated with the abrupt discontinuation. 
Patients using antipsychotics for neuropsychiatric conditions with the exception of dementia 
were excluded, as well as delirium, and terminally ill patients. 
Procedure 
Prior to the study, the medical and nursing staff of the participating geriatric wards was 
informed with regard to the study.  Information was given about the rationale for conducting 
this study, explaining that undertaking antipsychotic discontinuation efforts should be 
embedded in usual care practice.  Physicians and nurses were asked to contact the principle 
investigator when patients on antipsychotics were admitted to the hospital.  Further screening 
of the patients was done by the researcher, based on medical records, contact with GP and 
family members.    
Informed consent was collected from the participants, and/or their proxy.  When the patient 
was found eligible, the treating physician was asked to give the order to cease the 
antipsychotic treatment.  
A baseline neuropsychiatric inventory (NPI) was assessed by interviewing a responsible 
nurse, general practitioner (GP) or family member having close contact with the patient in the 
last four weeks before abrupt antipsychotic discontinuation was started.  
Study participants were meticulously observed by the physician and the nursing staff during 5 
consecutive days after the abrupt discontinuation. The observers used a checklist (see further) 
deliberately designed for this study (based on literature) to detect possible withdrawal 
symptoms.  This checklist was filled out three times a day by the early, late, and night nursing 
shift.  
One month after the date of discontinuation, the NPI was re-assessed by interviewing the 
responsible nurse or treating physician.  When the patient was discharged from the hospital, 
the follow-up was performed by telephone interview of the main caregiver, head nurse 
(nursing home) or GP.   
Data collection  
We collected administrative data (e.g. reason of hospital admission, length of hospital stay) 
and clinical data of all study participants.  Administrative data  also included Activities of 
Daily Living (ADL)
16
 which ranks the six functions of bathing, dressing, toileting, 
transferring, continence, and feeding.    
Clinical data included type of dementia, MMSE and clinical problems (retrieved from the 
medical records).    
The main outcome measure for this study was the NPI which covers twelve domains of 
behavioural and neurovegetative symptoms: delusions or paranoia, visual and auditory 
hallucinations, agitation or aggression, depressed mood or dysphoria, anxiety, elation or 
euphoria, apathy or indifference, disinhibition (impulsive), irritability or lability (decreased 
coping), motor disturbance (pacing, compulsive behaviours), night-time behaviour problems 
(e.g. sleep disturbance), appetite or eating problems (e.g. weight loss).    
The antipsychotic withdrawal checklist was developed based on the literature
17,18
 and 
included four psychological symptoms (anxiety, restlessness, insomnia, hallucinations), and 
ten physical symptoms.    
Malignant neuroleptic syndrome is a serious but rare event described when antipsychotic 
doses are augmented but also when antipsychotics are withdrawn
19
. This event was also 
included on the list and highlighted as a dangerous adverse event.  The checklist also allowed 
for nurses’ observations of other symptoms during the consecutive five days follow-up. 
Data handling  
The six domains of ADL were summed into a physical dependency score.  The higher the 
score, the more physically dependent (total score ranging from minimum 6 to maximum 24). 
The NPI which covers twelve neuropsychiatric domains, differentiates in frequency (absent, 
or a range from 1-4) and severity of symptoms (range 1-3).  We calculated each item by 
multiplying frequency and severity.  The higher the score, the more severe the 
neuropsychiatric item (ranging from minimum 1 to maximum 12 per item).  We also 
calculated a total NPI score that ranged from minimum 12 to a theoretical maximum of 144.  
The items of the withdrawal checklist (psychological and physical) were calculated into a 
total score, indicating the frequency of withdrawal symptoms per shift and per day. 
Statistical analysis  
The data was analysed using the Statistical Package for Social Sciences 19.0 (SPSS, Inc., 
Chicago, IL, USA). Differences, comparison of means between groups, and associations were 
analyzed through cross-tabulation, variance analysis, and correlations. The level of significance 
was set at p <.05.  
For data analysis, the study population was divided into two subgroups: a successfully 
discontinued group and a relapse group.  Successful discontinuation was defined as still being 
antipsychotic-free, one month after the date of abrupt discontinuation.  
We explored baseline differences among the two groups as well as mean changes in the 12 
NPI domains before and one month after antipsychotic discontinuation.  Also, we performed 
an analysis on NPI clusters to detect differences in larger defined areas being mood (i.e. 
euphoria, depression, apathy, appetite), restlessness (i.e. aberrant motor activity, night-time 
behaviour problems, anxiety and disinhibition), psychosis (i.e. delusions and hallucinations) 
and agitation (i.e. agitation/aggression, irritability).  
The success or relapse over time (in days) was examined using Kaplan Meier survival 
analysis where an event was defined as the re-initiation of antipsychotics.  
Ethical considerations 
This study was approved by the Ethics Committee of the Ghent University Hospital  
(approval number 2010/662) and of Hospital Network Antwerp (ZNA) (approval number 
3751).  Abrupt discontinuation was approved by the treating physician in all cases.  A written 
informed consent was provided by the patient, and/or by proxy.   
Results 
 
Description of the institutions 
We included three institutions of which one university hospital, one general hospital and a 
specialised psychogeriatric clinic.  This clinic is specialised in dementia diagnostics and offers 
treatment strategies for patients with varying degrees of cognitive impairment.  
Study participants were recruited from the geriatric ward of the university hospital (30 beds) 
and the general hospital (48 beds) as well as from the specialised clinic (60 beds).    
The admission profile varies between the institutions with acute admissions and short hospital 
stay in the university hospital, while in the general hospital there is a mix of acute admissions 
and longer hospitalisations pending institutionalisation.  The specialised clinic partially acts as 
a transition place pending institutionalisation, resulting in a longer hospital stay. 
Description of the population 
We enrolled 40 patients in the study (March-November 2011). Study participants had a mean 
age of 84 years (range 67-95) and were in 53% male.    
Figure 1.  Flowchart of the study
Recruitment
Study start in 40 participants
n=18 specialised psychogeriatric clinic 
n=13 university hospital
n=9 general hospital
    
  relapse n=2
Successful discontinuation
after 5 days follow-up
n=38
relapse n=6
Successful discontinuation
after 1 month follow-up
n=31
Drop out n=3
 
Patients had high physical dependency scores with a mean ADL of 16 (range 6-24) and had 
severe cognitive impairment (mean MMSE 16, range 4-25).  In 34 patients, there was a 
clinically confirmed diagnosis of dementia.  In the remaining six patients, there was no 
established diagnosis of dementia, but cognitive impairment existed (based on the MMSE) 
with behavioural disturbances for which antipsychotics were prescribed.   
Table 1. Description of the study population (n=40) and the antipsychotic use
General patient characteristics
Age (mean, range) 84 (67-95)
Females (%) 48
Physical dependency score (mean, range) 17 (6-24)
Mini Mental State Examination (mean, range) 16 (4-25)
Clinical problems n
Hypertension 20
Vascular disease 9
Heart failure 5
Atrial fibrillation 5
Myocardial infarct 1
Cerebrovascular stroke 14
Epilepsy 6
Parkinson's disease 6
Diabetes 6
Renal failure 5
Prostate disease 2
Reason of hospital admission n
General deterioration¹ 17
Cognitive problem² 12
Physical illness 8
Falls 3
Length of hospital stay
3 
20 (8-417)
(days) (median, range)
Antipsychotic use %
Atypicals 73
Risperidone 48
Quetiapine 13
Olanzapine 8
Clozapine 4
Typicals 27
Haloperidol 19
Others 8
¹ included physical deterioration, as well as condition of neglect and/or pending institutionalisation
² defined as acute and severe confusion and/or cognitive diagnostics
3
 length of study follow-up was 30 days, but a long mean length of stay was mainly due to patients 
from the specialised neuropsychiogeriatric clinic who were already already long-term hospitalised before study-start  
 
 
Study participants suffered in 55% from Alzheimer’s dementia, in 15% vascular dementia, in 
15% dementia associated with Parkinson’s disease, and in 15% there was no medical 
diagnosis of dementia (cognitive impaired).      
The main reason for admission was general deterioration (Table 1).  A small variance was 
found between the institutions with a physical illness as the main reason for admission in the 
university hospital, and cognitive diagnostic work-up as the main reason for admission in the 
specialised psychogeriatric clinic.  The length of hospital stay varied per institution with a 
median of 20 days in the university hospital, 18 days in the general hospital and 168 days in 
the memory clinic.  Study participants had several underlying diseases, with cardiovascular 
problems in 83% of patients.    
Description of antipsychotic use  
All patients received antipsychotics at stable doses.  In eight patients there was duplicate use.   
Atypical antipsychotics accounted for 73% of the total use.  Median (range) daily doses of the 
main prescribed antipsychotics were: risperidone 1 mg (0.25-2), quetiapine 82 mg (50-100), 
olanzapine 5 mg (5-10), haloperidol 2 mg (1-5).  In six patients a geriatric psychiatrist was 
consulted regarding the abrupt discontinuation because of higher doses than the recommended 
geriatric doses.  
We asked responsible nurses to indicate the main problem for which the patient was using 
antipsychotics.  They indicated antipsychotic use for restlessness and agitation in 63%, 
aggression in 11%, delusion and hallucinations in 11%, depression in 10% and anxiety in 5%. 
Completion  
All study participants completed at least the consecutive five days follow-up period after the 
abrupt discontinuation.  The follow-up NPI scores after one month could only be obtained  for 
37 patients, since three patients had dropped out due to unrelated death (cancer and 
pneumonia) (n=2) or adverse event (i.e. fall 14 days after discontinuation) (n=1).    
During the consecutive five days follow-up, two study participants relapsed to antipsychotic 
use due to recurring delusions, hallucinations and/or agitation/aggression.   
 
 
At one month follow-up, four more participants had relapsed to antipsychotics of which two 
cases were restarted during hospitalisation, and two cases restarted after discharge at the 
nursing home.  In three of these cases, patients suffered from delusions, hallucinations and/or 
agitation/aggression.   
Survival analysis investigated the time to relapse and revealed that the success rate over time 
was 95% after 5 days, and 85% after 30 days (Figure 3).  Mean calculated survival time was 
25 days.  
Baseline neuropsychiatric inventory  
Baseline NPI scores indicated that the majority of problems were behavioural symptoms 
rather than psychological symptoms.  Night-time behaviour problems in addition to 
agitation/aggression were the predominant disturbances.  The study population had a mean 
total NPI score of 21 (SD 12) (Table 2).    
When differentiating in baseline symptom NPI scores between the successfully discontinued 
and relapse group, we found higher baseline scores for the majority of NPI domains in the 
relapse group, but only statistically significant for the domain of night-time behaviour 
problems and for hallucinations. Also, when comparing the overall mean NPI between 
successful and relapse group, there was a significant higher score for the relapse group 
(p=0.007, Table 2). 
 
 
 
 
 
 
 
 
 
 
Table 5.2  Neuropsychiatric inventory scores at baseline and at one month follow-up 
 
 
Withdrawal symptoms  
All study participants completed the consecutive five days follow-up with monitoring three 
times a day of withdrawal symptoms by using a checklist.  Mild withdrawal symptoms were 
observed in 72% of patients, peaking on the day two (53%) and day three (48%) and more 
often occurring at night.  Psychological symptoms were reported in 67% of patients while 
physical symptoms occurred in 15% (Table 3 and Figure 2). 
 
 
 
Table 5.3  Percentage of patients with withdrawal symptoms during the consecutive five days    
                   follow-up 
Day 1 Day 2 Day 3 Day 4 Day 5 Total
Psychological symptoms
Unrest/agitation 35% 45% 40% 15% 15% 64%
Insomnia 20% 28% 25% 10% 8% 48%
Anxiety 3% 3% 3% 3% 0% 5%
Hallucinations 0% 8% 15% 5% 0% 25%
Total psychological symptoms 41% 50% 55% 21% 8% 67%
Total physical symptoms* 5% 5% 8% 3% 0% 15%
Total withdrawal symptoms 45% 53% 48% 23% 8% 72%
*nausea, emesis, diarrhea, vertigo, rhinorrhoea, increased appetite, anorexia, diaphoresis, dyskinesia, parageusia  
Figure  5.2  Prevalence of withdrawal symptoms occurring during the day, evening or night 
 
 
 
 
 
 
 
Figure 5.3  Survival analysis with antipsychotic relapse defined as the event over time (days) 
 
Changes in NPI scores 1 month after antipsychotic discontinuation  
Study participants with successful antipsychotic discontinuation after one month had 
significantly improved (p=0.003) on the total mean NPI score, decreasing from 18.1 (SD 
12.6) to 12.4 (7.9).   They had lower mean NPI scores on 11 out of 12 NPI domains, but most 
of these improvements were not statistically significant, except for the item hallucinations 
(p=0.017).  A small decrease in total mean NPI of the relapse group while back on 
antipsychotics was from 30.7 (SD 7.3) to 27.2 (SD 11.8) (p=0.345).  There was a non-
significant trend to improvement on six out of twelve domains, especially for irritability, 
delusions, hallucinations and anxiety.  In this group we found non-significant increasing 
domain scores for agitation/aggression, apathy and disinhibition.   
In the successful group, there were benefits for the cluster mood as well as for the cluster 
psychosis with lower mean scores compared to baseline. In the relapse group, there was no 
deterioration associated with the abrupt discontinuation and subsequent resumption of therapy 
with possibly benefits for the cluster restlessness, agitation and psychosis.  For the cluster 
mood there was no change (Table 2).    
 
 
 
Discussion 
 
To our knowledge, this study is the first to investigate the effects of abrupt antipsychotic 
discontinuation in cognitively impaired, geriatric inpatients with attention to withdrawal 
phenomena and neuropsychiatric symptom changes over time.    
Mild withdrawal symptoms were common after abrupt discontinuation, but these symptoms 
weaned quickly over time, and led to relapse of antipsychotics in only a small minority of 
patients (n=2).  At one month follow-up, 85% of participants were still off antipsychotics.  
We anticipated that patients discharged from the hospital to the nursing home would rapidly 
resume antipsychotic treatment, but this was not the case at one month follow-up.    
Patients who relapsed to antipsychotics had more severe baseline symptoms, and needed 
resumption of therapy. Our study confirmed that high baseline antipsychotic doses and severe 
baseline behavioural scores are predictive for relapse and deteriorating behavioural effects 
after discontinuation
10,14
.  However, patients relapsing to antipsychotics showed no residual 
effects or deteriorating behaviour as a result of a period of discontinuation and subsequent 
resumption of therapy, still leading to a trend of some modest improved NPI domains.   
Patients who were successfully discontinued shared a clinically relevant and statistically 
significant improvement on the total mean NPI score and some of the subscores.  Also other 
studies have confirmed our finding that the course of behavioural symptoms improves or 
remains stable after antipsychotic discontinuation
4,10
.  Our study findings suggest that 
behavioural disturbances in dementia are fluctuating and cognitively impaired older persons 
often do not benefit from long-term antipsychotic treatment.  Systematically performed 
discontinuation efforts in clinical practice are needed to differentiate between patients where 
antipsychotics have no added value and patients where the benefits outweigh the risks.  
Gradual tapering is often recommended because of potential withdrawal symptoms, and is the 
result from studies with schizophrenic patients
17,20,21
 using higher doses of antipsychotics than 
older persons for the indication of BPSD.  Furthermore, there is little information about the 
effects of gradual versus abrupt antipsychotic discontinuation in older persons with dementia, 
and the relationship with dosages, nor a standardised discontinuation schedule.  We found that 
abrupt discontinuation of antipsychotics is feasible in older persons who are mostly using 
antipsychotics chronically in lower doses for their BPSD.   
However, monitoring of withdrawal symptoms is always necessary and caution is still 
required in patients using high antipsychotic doses. 
Limitations  
We performed an observational uncontrolled pilot study in which we assessed the feasibility 
and the effects of abrupt antipsychotic discontinuation, as a part of usual care in a real-world 
setting.  Despite the inclusion of three institutions, we still had a small sample, mainly due to 
some resistance at the start of the study with consequences on the ease of recruitment. The 
inherent limitation of a pilot study is often the small sample, and the consecutive lack of 
sufficient power to make strong statements based on the results.  Also, subgroup analyses 
(e.g. type of dementia) were not possible due to our small sample.   Nevertheless, in our 
opinion, a pilot study exploring abrupt antipsychotic discontinuation was necessary before 
performing a large intervention study.  
A potential selection bias cannot be excluded for potentially eligible patients in whom treating 
physicians did not perform discontinuation.  Our study included cognitively impaired long-
term users in which antipsychotic discontinuation should be considered according to best 
practice in a ‘real world’ setting, excluding patients with psychiatric co-morbidities and acute 
behavioural problems in which continuation of antipsychotic treatment may be justified.  
Therefore, our study is however not representative in these patients.   
As the study progressed, perceptions and attitudes positively changed when clinical 
improvements were seen in patients. The clinical improvement mainly included the clearing 
up of the antipsychotic induced drowsiness and sedation.  Unfortunately, we could not further 
explore the process of clearing up mainly because of the lack of a standardised assessment 
tool to measure these rather ‘clinical’ effects in cognitively impaired older persons. 
 It is possible that part of the high success rate and NPI improvement in successfully 
discontinued patients could be the consequence of a higher tolerability of behavioural 
problems, more knowledge, and altered perceptions, induced by the study.    
We performed a pilot study to detect whether abrupt discontinuation would be feasible, and 
deliberately have chosen a hospital setting in order to detect adverse effects associated with 
the abrupt discontinuation in due time.  The detection of withdrawal symptoms was recorded 
by nurses and by the researchers based on a specifically developed but not validated checklist.  
There are few studies on antipsychotic withdrawal symptoms
17,18
 and there is no validated 
tool to observe them, in contrast to the field of benzodiazepine withdrawal
22
.    
 
 
We recorded a high prevalence of mild withdrawal symptoms mainly because our checklist 
was very sensitive and symptoms were recorded three times a day (day, evening and night).  
However, the symptoms weaned quickly over time suggesting that the symptoms were in fact 
withdrawal symptoms associated with the abrupt discontinuation.    
Three patients dropped out, of which two participants died due to unrelated physical illness.  
Drop out due to death in older patients was expected since our population consists of frail 
older persons being hospitalised.  One participant had an adverse event (fall) two weeks after 
the discontinuation, which was retrospectively reported to the researchers.  
The relation between this adverse event and the antipsychotic discontinuation is unclear, 
knowing that older people have an increased risk of falling with several underlying factors, 
and that falls are frequent, also among non-antipsychotic users.   
Implications for research  
The results of this pilot study with regard to abrupt discontinuation suggest that abrupt 
discontinuation is feasible, and that larger confirmatory intervention studies controlling for 
type of dementia and potentially confounding factors in a hospital or nursing home setting 
with long-term follow-up, are needed.  Antipsychotic discontinuation in a hospital setting 
should be further explored as an alternative to discontinuation programs in the nursing home, 
unburdening nursing home staff from the decision making and monitoring after the 
discontinuation.  Discontinuation programs within hospitals or nursing homes should start 
with educational sessions for nurses and doctors to guarantee participation and involvement.
  
Implications for practice  
Abrupt antipsychotic discontinuation in older individuals with BPSD appears to be feasible 
with a high success rate after one month. Discontinuation efforts are needed to identify 
patients in whom continuing antipsychotics have no added value, and patients in whom 
continuing treatment may be justified.  Credible efforts should be undertaken to convince 
doctors and nursing staff in hospitals and nursing homes of the importance of antipsychotic 
discontinuation.  
 
 
5.1 CONCLUSION  
 
Abrupt antipsychotic discontinuation appears to be feasible.  Systematically performed 
discontinuation efforts in clinical practice are needed to differentiate between patients where 
antipsychotics have no added value and patients where the benefits outweigh the risks.   
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